> ## Content Index
> Fetch the complete content index at: https://news.arxhq.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nuvectis expands pipeline with Haisco license for two clinical-stage compounds
- URL: https://news.arxhq.com/nuvectis-haisco-license/
- Published: 2026-06-23T12:00:00.000Z
- Updated: 2026-09-08T09:54:22.000Z
- Description: Ex-China rights to HSK42360 and HSK39297. $40 million upfront and near-term, up to $1.42 billion in milestones.
- Author: Arx Staff
- Tags: Client news, Deals

Nuvectis announced a strategic portfolio expansion via an exclusive license with Haisco Pharmaceutical Group for two potentially best-in-class clinical-stage compounds.

Under the agreement, Haisco granted Nuvectis exclusive rights outside Greater China (and, for one compound, outside India and certain Southeast Asia territories) to HSK42360, a BRAF paradoxical breaker, and HSK39297, a once-daily complement Factor B inhibitor.

Haisco will receive $40 million in upfront and near-term payments and is eligible for up to $1.421 billion in additional milestones, plus tiered royalties.

The transaction transforms Nuvectis into a later-stage company spanning complement-mediated disease and oncology.

[Read the full release](https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candidates-in-oncology-and-complement-indications-302807803.html?ref=news.arxhq.com)